Abstract
Background Gastrointestinal parasites are generally associated with lower-income countries in tropical and subtropical areas, but they are also prevalent in low-income and extreme low-income communities in the Southern United States. To date, studies characterizing the epidemiology of gastrointestinal parasites in the United States are limited, resulting in little comprehensive understanding of the challenge. This study investigates the environmental contamination of gastrointestinal parasites in the Southern United States by determining the contamination rate and burden of each parasite in five low-income communities.
Methods A total of 499 soil samples of approximately 50g were collected from public parks and private residences in Alabama, Louisiana, Mississippi, South Carolina, and Texas. A novel technique utilizing parasite floatation, filtration, and bead-beating was applied to concentrate and extract parasite DNA from samples and detected via multi-parallel qPCR.
Findings qPCR detected Blastocystis spp (19.0%), Toxocara cati (6.01%), Toxocara canis (3.61%), Strongyloides stercoralis (2.00%), Trichuris trichiura (1.80%), Ancylostoma duodenale (1.42%), Giardia intestinalis (1.40%), Cryptosporidium spp (1.00%), Entamoeba histolytica (0.201%), and Necator americanus (0.200%). Overall parasite contamination rates varied significantly between communities: Western Mississippi (46.88%); Southwestern Alabama (39.62%); Northeastern Louisiana (28.24%); Southwestern South Carolina (27.03%); and South Texas (6.93%) (p < 0.0001). Toxocara cati DNA burdens were greater in communities with higher poverty rates, including Northeastern Louisiana (50.57%) and Western Mississippi (49.60%) compared to Southwestern Alabama (30.05%) (p = 0.0011).
Interpretation This study demonstrates the environmental contamination of parasites and their relationship with high poverty rates in communities in the Southern United States.
Funding This work was supported by the Maternal and Infant Environmental Health Riskscape (MIEHR) Center of Excellence on Environmental Health Disparities Research, NIMHD grant #P50 MD015496
Evidence before this study Several research articles on parasites in the Southern USA were used to determine the extent of parasitosis in the selected regions (Mckenna et al, Am J Trop Med Hyg 2018; Singer et al, Am J Trop Med Hyg 2020; Bradbury et al, Emerg Infect Dis 2021). Criteria used included terms hookworm, soil-transmitted helminths, protozoa, and parasites in the United States. The most recent parasite prevalence studies indicate areas with 62.9% Blastocystis, 34.5% hookworm (Necator americanus), 16.5% Strongyloides stercoralis, 5.2% Toxocara, 2.9% Cryptosporidium, 2.3% Giardia intestinalis, and 1.8% Entamoeba histolytica from human serum or stool samples. These studies focus on human parasite infections, but there are no current published studies on environmental parasite surveys in the Southern US. The parasites in this study all have part of their life-cycle in soil and can directly infect humans living in these areas.
Added value of this study Our work expands the current understanding of prevalence of parasites in the Southern US soil from built environments. We further correlate the type of parasites and their intensity of soil contamination with higher poverty rates.
Implications of all the available evidence These parasitic infections represent a major source of contamination in the built environments and their association with poverty. This study will help focus public policy on the potential risks that environmental parasites have on human health. It further describes the high contamination rates in the USA, a high-income country.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Maternal and Infant Environmental Health Riskscape (MIEHR) Center of Excellence on Environmental Health Disparities Research, NIMHD grant #P50 MD015496.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
